Pavaka Wound Care Graduates from Rev1's Customer to Capital Accelerator, Pitches at Investor Showcase
Updated: 3 days ago
COLUMBUS, Ohio — November 20, 2025 — Pavaka Wound Care has completed Rev1 Ventures' Fall 2025 Customer to Capital accelerator. CEO and Co-Founder Brent Toto presented the company at the program's Investor Showcase in Columbus.

Pavaka entered the 14-week accelerator in August as one of seven companies in Rev1's fall cohort. The program pairs founders with Rev1's team and mentors to secure early customers, strengthen competitive positioning, build financial and capital models, and prepare to engage investors. The Investor Showcase is the program's capstone, where graduating companies present to investors, partners and the Columbus innovation community.
Toto's pitch covered the clinical problem Pavaka is working on. Chronic and acute wounds complicated by multidrug-resistant bacteria and biofilms burden patients, health systems and military medicine. He also introduced the company's investigational electroceutical dressing, which generates a low-level electric field at the wound surface and is built on technology exclusively licensed from The Ohio State University.
Pavaka made substantial progress during the accelerator. It refined its regulatory strategy, advanced design-for-manufacturing work on a second-generation dressing with its Ohio manufacturing partner, and deepened conversations with clinicians and military medicine stakeholders. A day earlier, Pavaka presented its plan to Rev1 for a Concept Contract award to support next-generation dressing development.
Rev1 celebrated the graduating companies on social media in the days that followed, and the independent newsletter Midwest HardTech recapped the cohort's showcase.
Pavaka thanks the Rev1 Ventures team, the program mentors and its fellow cohort companies for 14 weeks of candid feedback and support.
For Pavaka, the Investor Showcase capped a busy 2025. In January the company announced its exclusive Ohio State license, in April it received the Ohio Department of Development's Technology Validation and Start-up Fund award, and in July it completed Rev1's Concept to Customer program as the participants' favorite.
Pavaka plans to keep working closely with Rev1 Ventures as it moves into 2026.
"The accelerator pushed us to answer the hard questions about customers, capital and execution. We walked off that stage a stronger company than the one that walked in, in August." — Brent Toto, CEO and Co-Founder
Investigational device: Pavaka's electroceutical wound dressing has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale.
About Pavaka Wound Care: Pavaka Wound Care is a Columbus, Ohio–based medical device company developing an electroceutical advanced wound dressing for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms. Built on technology exclusively licensed from The Ohio State University, the investigational dressing generates a low-level electric field at the wound surface. Pavaka was co-founded by CEO Brent Toto and CTO Frank Fischer. Learn more at www.pavakawoundcare.com.



Comments